Nektar Therapeutics Announces Initiation of a Phase 1b Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, in Patients with Systemic Lupus Erythematosus
Go back to Nektar Therapeutics Announces Initiation of a Phase 1b Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, in Patients with Systemic Lupus Erythematosus| Nektar Therapeutics (NASDAQ: NKTR) | Delayed: 66.84 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $66.84 | 52 Week High | $19.98 | |||
| Open | $66.84 | 52 Week Low | $10.52 | |||
| Day High | $66.84 | P/E | N/A | |||
| Day Low | $66.84 | EPS | $-1.45 | |||
| Volume | 1,240 | |||||
